Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis
Open Access
- 29 September 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (10), 3224-3238
- https://doi.org/10.1002/art.23884
Abstract
Objective To investigate the expression of vascular endothelial growth factor (VEGF) in muscle biopsy specimens and serum from patients with polymyositis and patients with dermatomyositis compared with that in healthy control subjects. Methods Muscle biopsy specimens from 33 patients with polymyositis or dermatomyositis and 15 healthy control subjects and serum samples from 56 patients and 56 healthy control subjects were analyzed. Patients were categorized into 3 groups, depending on disease duration and the presence or absence of inflammatory infiltrates. The expression of VEGF and the vessel marker CD31 in muscle was analyzed by immunohistochemistry, the expression of VEGF messenger RNA (mRNA) was analyzed by in situ hybridization, and serum levels of VEGF were determined by enzyme-linked immunosorbent assay. Results Patients with polymyositis or dermatomyositis in the early or chronic phase without inflammatory infiltrates had a decreased total number of capillaries compared with healthy individuals. In patients with early disease without inflammatory infiltrates, the number of VEGF-expressing muscle fibers was increased compared with that in control subjects, whereas VEGF expression was unchanged in the chronic phase of disease. In patients with established disease with inflammatory infiltrates, total VEGF expression was high compared with that in healthy control subjects. In healthy control subjects, VEGF was expressed in endothelial cells and in occasional muscle fibers. VEGF mRNA was expressed in muscle fibers in both healthy individuals and patients. The level of serum VEGF was significantly increased in patients compared with control subjects. Conclusion Our observations support a role of VEGF in the early phases of polymyositis and dermatomyositis. A reduced number of capillaries could lead to induction of VEGF expression in muscle fibers. Furthermore, differences in molecular expression during certain phases of disease may help in the development of specific therapeutic algorithms in the treatment of myositis.Keywords
This publication has 45 references indexed in Scilit:
- Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic DifferentiationMolecular Biology of the Cell, 2008
- Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesisCancer Science, 2007
- Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic InjuryThe American Journal of Pathology, 2007
- Down‐regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroidsArthritis & Rheumatism, 2004
- Interleukin‐1α (IL‐1α) promotes angiogenesis in vivo via VEGFR‐2 pathway by inducing inflammatory cell VEGF synthesis and secretionThe FASEB Journal, 2002
- Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cellsKidney International, 2000
- High endothelial venules (HEVs): specialized endothelium for lymphocyte migrationImmunology Today, 1995
- Hypoxia Upregulates the Synthesis of TGF-β1 by Human Dermal FibroblastsJournal of Investigative Dermatology, 1991
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- Microvascular Deposition of Complement Membrane Attack Complex in DermatomyositisNew England Journal of Medicine, 1986